It’s Time to Finally Kill the Zombies; Comment on “Universal Pharmacare in Canada”

The movement for a national pharmacare plan in Canada is growing, but at the same time the multinational pharmaceutical companies and their supporters are critical of such a move. The three major arguments that they make are that all that is needed is to “fill in the gaps,” ie, cover those who curre...

Full description

Bibliographic Details
Published in:	International Journal of Health Policy and Management
Main Author:	Joel Lexchin
Format:	Article
Language:	English
Published:	Kerman University of Medical Sciences 2020-12-01
Subjects:	canada drug expenditures formulary pharmacare pharmaceutical industry
Online Access:	https://www.ijhpm.com/article_3736_0fb325cb7ff338d1be1f446f9644fa53.pdf

Similar Items

Understanding the Battle for Universal Pharmacare in Canada; Comment on “Universal Pharmacare in Canada”
by: Marc-André Gagnon
Published: (2021-03-01)

Separated at Birth: The Politics of Pharmacare for All in Canada and Medicare for All in the United States; Comment on “Universal Pharmacare in Canada”
by: Carolyn Hughes Tuohy
Published: (2021-03-01)

National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability; Comment on “Universal Pharmacare in Canada: A Prescription for Equity in Healthcare”
by: Nigel S. B. Rawson
Published: (2020-12-01)

Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare
by: Jaden Brandt, et al.
Published: (2018-12-01)

Putting National Pharmacare on the Federal Agenda
by: Michel Grignon, et al.
Published: (2019-08-01)

Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis
by: Joel Lexchin
Published: (2018-12-01)

Public–private partnership alternative for a national pharmacare program in Canada
by: Eric Nauenberg, et al.
Published: (2023-02-01)

THE CONTEMPORARY METHODOLOGICAL APPROACHES FOR STANDARDIZATION OF MEDICINES FOR MILITARY HOSPITALS
by: A. G. Golub, et al.
Published: (2015-09-01)

Access and use of WHO essential medicines in Italy
by: Alessandro Petrella, et al.
Published: (2023-10-01)

Quality and quantity of data used by Health Canada in approving new drugs
by: Joel Lexchin, et al.
Published: (2023-11-01)

Use of an Innovative Pharmaceutical Class Scoring Tool for Prioritized Annual Formulary Review
by: Holly Sheldon, et al.
Published: (2022-06-01)

The role of pharmacoeconomics in current Indian healthcare system
by: Akram Ahmad, et al.
Published: (2013-01-01)

pH determination as a quality standard for the elaboration of oral liquid compounding formula
by: Silvia Vázquez-Blanco, et al.
Published: (2018-11-01)

Impact of hospital formulary intervention on carbapenem use: a segmented time-series analysis of consumption and a propensity score-matched non-inferiority study of treatment efficacy
by: Nakaba Okamura, et al.
Published: (2025-01-01)

A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study
by: Joel Lexchin
Published: (2021-12-01)

Neonatal Drug Formularies—A Global Scope
by: Dotan Shaniv, et al.
Published: (2023-05-01)

Individualising drug dispensaries in a university hospital
by: M Jordan, et al.
Published: (2007-01-01)

Commercializing Personal Health Information: A Critical Qualitative Content Analysis of Documents Describing Proprietary Primary Care Databases in Canada
by: Sheryl Spithoff, et al.
Published: (2023-12-01)

Pharmacoeconomic aspects of pharmaceutical ethics
by: Huk Karina Ruslanivna, et al.
Published: (2022-01-01)

A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines
by: Asma Abubakr Mustafa, et al.
Published: (2010-12-01)

The Formulary System in the Republic of Kazakhstan in 2012–2014
by: G. K. Zhussupova
Published: (2016-12-01)

Assessing the Equitable Use of Formulary Drug Tier Systems
by: Vishwanauth Persaud, et al.
Published: (2025-08-01)

Implementation of a hospital antimicrobial stewardship program to improve vancomycin use in Cyprus: Challenges and opportunity
by: Panagiotis Papastergiou, et al.
Published: (2022-12-01)

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
by: Epstein RS
Published: (2021-09-01)

National Pharmacare in Canada: 2019 or Bust?
by: Owen Adams, et al.
Published: (2017-03-01)

National Pharmacare in Canada: 2019 or Bust?
by: Owen Adams, et al.
Published: (2017-03-01)

A Descriptive Study to Determine Prescription Compliance of Dispensary in a Polyclinic Outpatient Department of a Tertiary Care Hospital
by: M. Vinodh Kumar, et al.
Published: (2025-05-01)

Equity zombies in Canada’s blue economy: a critical feminist analysis for equitable policy implementation
by: Christine Knott, et al.
Published: (2024-03-01)

Factors affecting decisions of an HMO Drug Exemptions Committee on individual patient requests for coverage of non-formulary drugs
by: Yael Topol, et al.
Published: (2024-07-01)

Understanding drug exceptional access programs (DEAPs) in Canada, and their associated social and political issues
by: Pierre-Marie David, et al.
Published: (2024-03-01)

Impact of Formulary Restrictions on Antiepileptic Drug Dispensation Outcomes
by: Darshan Mehta, et al.
Published: (2020-05-01)

Lecture 2—What Is a Formulary, Anyway? (Or the Cliff Notes Version of Drug Stewardship and Expense Control)
by: Richard H. Parrish
Published: (2018-07-01)

Assessing oncology providers attitudes and practices toward nonformulary drugs and mapping current obstacles in Saudi Arabia
by: Nora Alkhudair, et al.
Published: (2023-12-01)

Prêter son nom et simuler des transactions. Des stipulations d’Abû Ja‘far al-Ṭaḥâwî (ixe-xe siècles) aux consultations et actes juridiques des xviie-xviiie siècles
by: Brigitte Marino
Published: (2010-07-01)

Regional Formularies in Italy: current state and future perspectives
by: Alberto Bortolami, et al.
Published: (2024-03-01)

Corporate Income Tax Avoidance in the European Arena – Evidence and Remedies
by: Tibor Pál, et al.
Published: (2015-12-01)

Antimicrobial stewardship and drug formulary restrictions during COVID-19: what is restricted and who decides?
by: Alfredo J. Mena Lora, et al.
Published: (2023-01-01)

Attitude and perception of pharmacists and healthcare professionals about the criteria used in drug formulary selection in the United Arab Emirates
by: Sabaa Saleh Al‑Hemyari, et al.
Published: (2022-12-01)

Drug utilisation and off-label use of medications in anaesthesia in surgical wards of a teaching hospital
by: Amol E Patil, et al.
Published: (2015-01-01)

The growth strategies of a global pharmaceutical company: a case study of Aspen Pharmacare Holdings Limited
by: Victoria Margaret Hodgon, et al.
Published: (2017-05-01)